Advisor OS’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.68M Sell
7,235
-35
-0.5% -$35.8K 0.58% 32
2026
Q1
$6.69M Buy
7,270
+529
+8% +$536K 0.48% 37
2025
Q4
$7.24M Buy
6,741
+668
+11% +$639K 0.58% 32
2025
Q3
$4.63M Buy
6,073
+630
+12% +$469K 0.4% 36
2025
Q2
$4.24M Buy
5,443
+82
+2% +$63.7K 0.42% 36
2025
Q1
$4.43M Buy
5,361
+18
+0.3% +$15K 0.5% 32
2024
Q4
$4.12M Buy
5,343
+240
+5% +$199K 0.48% 35
2024
Q3
$4.52M Buy
5,103
+413
+9% +$371K 0.45% 37
2024
Q2
$4.25M Buy
4,690
+159
+4% +$127K 0.47% 38
2024
Q1
$3.53M Buy
4,531
+492
+12% +$350K 0.41% 42
2023
Q4
$2.35M Buy
4,039
+1,377
+52% +$804K 0.31% 61
2023
Q3
$1.43M Buy
2,662
+242
+10% +$125K 0.21% 89
2023
Q2
$1.13M Buy
2,420
+1,332
+122% +$559K 0.19% 109
2023
Q1
$374K Buy
1,088
+69
+7% +$23.3K 0.09% 179
2022
Q4
$373K Buy
1,019
+148
+17% +$52.5K 0.1% 166
2022
Q3
$282K Buy
871
+41
+5% +$13K 0.09% 164
2022
Q2
$270K Hold
830
0.08% 180
2022
Q1
$237K Sell
830
-305
-27% -$78.5K 0.07% 190
2021
Q4
$314K Buy
1,135
+38
+3% +$9.63K 0.06% 207
2021
Q3
$253K Sell
1,097
-14
-1% -$3.46K 0.06% 205
2021
Q2
$255K Buy
1,111
+14
+1% +$2.81K 0.05% 204
2021
Q1
$205K Buy
+1,097
New +$215K 0.05% 191

Other funds holding LLY

Advisor OS's LLY Position: Q2 2026 in Review

Advisor OS reduced its Eli Lilly (LLY) stake by 0.48% in Q2 2026, selling an estimated $35.8K and leaving 7,235 shares worth $8.68M. The position accounts for 0.58% of the portfolio, ranked #32.

Advisor OS first reported a position in LLY in Q1 2021 and has held it in 22 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Advisor OS held 7,235 shares of Eli Lilly worth $8.68M as of Q2 2026.
  • Advisor OS sold 35 Eli Lilly shares in Q2 2026, an estimated $35.8K.
  • Eli Lilly made up 0.58% of Advisor OS's portfolio in Q2 2026, its #32 holding.
  • Advisor OS first reported a position in Eli Lilly in Q1 2021 and has held it in 22 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Advisor OS's 13F filing for Q2 2026, filed 5 Aug 2026.